ESMO Breast Cancer Virtual Meeting | Conference

Dr. Powell on the Risk of ILD with Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 8th 2021

Charles Powell, MD, MBA, discusses the risk of interstitial lung disease in patients with HER2-positive metastatic breast cancer treated with trastuzumab deruxtecan.

Datopotamab Deruxtecan Shows Encouraging Preliminary Safety, Efficacy in TNBC

May 8th 2021

The differentiated TROP2-directed antibody-drug conjugate datopotamab deruxtecan was found to have promising antitumor activity with a manageable safety profile in heavily pretreated patients with triple-negative breast cancer.

Retesting for HER2 Upon Breast Cancer Relapse May Provide New Therapeutic Opportunities

May 8th 2021

Approximately 30% of breast cancer tumors can covert from, or to, HER2-low status, underscoring the need to retest for HER2 expression upon relapse.

Bachelot Spotlights Impact of Tucatinib for CNS Metastases in HER2+ Breast Cancer

May 8th 2021

Thomas Bachelot, MD, discussed how to approach treatment of patients with HER2-positive breast cancer and CNS metastases and the impact of tucatinib in this population.

Shorter Duration of Adjuvant Trastuzumab Shows Long-Term Survival Benefit in Select HER2+ Early Breast Cancer

May 8th 2021

Although administering trastuzumab for 1 year in patients with HER2-positive early breast cancer continues to be standard, a 9-week de-escalation approach may be a reasonable option in a large proportion of the real-world HER2-positive population.

Dr. Voorwerk on Outcomes with Atezolizumab Plus Carboplatin in Metastatic Lobular Breast Cancer

May 7th 2021

Leonie Voorwerk, discusses outcomes with the combination of atezolizumab plus carboplatin in metastatic lobular breast cancer, which was evaluated as part of the phase 2 GELATO trial.

Dr. Bachelot on the Role of Tucatinib in HER2+ Breast Cancer With CNS Metastases

May 7th 2021

Thomas Bachelot, MD, PhD, discusses the role of the combination of tucatinib plus trastuzumab and capecitabine in patients with HER2-positive breast cancer who have central nervous system metastases.

Dr. Conte on Outcomes With 1 Year Vs 9 Weeks of Adjuvant Trastuzumab in HER2+ Breast Cancer

May 7th 2021

Pier Franco Conte, MD, discusses long-term outcomes with 1 year vs 9 weeks of treatment with adjuvant trastuzumab in patients with HER2-positive early breast cancer.

Ribociclib/Endocrine Therapy Improves OS Regardless of Age in Advanced HR+/HER2- Breast Cancer

May 7th 2021

Ribociclib plus endocrine therapy improved overall survival and post-progression outcomes in pre- or postmenopausal patients with hormone receptor–positive, HER2-negative advanced breast cancer irrespective of age.

Atezolizumab Plus Carboplatin Induces Early Efficacy Signals in Invasive Lobular Breast Cancer

May 7th 2021

Treatment with atezolizumab plus carboplatin demonstrated early clinical activity in patients with metastatic invasive lobular breast cancer, with slight trends toward increased clinical benefit in patients with triple-negative ILC and responders with higher PD-L1 expression, according to initial findings of the non-randomized phase 2 GELATO trial.

Breast Cancer Survivors Need More Tailored Follow-Up Care

May 7th 2021

Post-treatment care for breast cancer survivors must be personalized to address each survivor’s unique experiences.

Dr. Andre on Strategies to Improve Outcomes in Breast Cancer

May 28th 2020

Fabrice André, MD, PhD, discusses strategies to improve outcomes in patients with breast cancer.

Dr. Jerusalem on Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 28th 2020

Guy Jerusalem, MD, PhD, discusses the utility of fam-trastuzumab deruxtecan-nxki in HER2-positive breast cancer.

Addition of Veliparib to Carboplatin-Paclitaxel Increases PFS in HR+ Breast Cancer, TNBC

May 27th 2020

The PARP inhibitor veliparib increased progression-free survival in women with hormone receptor-positive breast cancer and triple-negative breast cancer who harbored a germline BRCA1/2 mutation when co-administered with carboplatin and paclitaxel, according to findings from the phase 3 BROCADE3 trial (NCT02163694).

Top Priorities Outlined in Next Decade of Breast Cancer Research

May 26th 2020

Developing diagnostics to identify the molecular drivers of breast cancer and model the mechanisms of disease progression will be a key priority of the investigative efforts aimed at improving patient outcomes in the field over the next decade.

LSZ102 Shows Encouraging Activity in Combination With Ribociclib, Alpelisib in ER+ Breast Cancer

May 26th 2020

LSZ102 was found to be well tolerated and demonstrate clinical activity in combination with either ribociclib or alpelisib in patients with estrogen receptor–positive breast cancer who have progressed on endocrine therapy.

Trastuzumab Deruxtecan Shows Efficacy in HER2+ Breast Cancer Brain Mets

May 24th 2020

Fam-trastuzumab deruxtecan-nxki (Enhertu) demonstrated continued benefit in patients with HER2-positive breast cancer who had stable, treated brain metastases at baseline.

Mindful Adaptation of Breast Cancer Treatment Necessary Amid COVID-19 Crisis

May 24th 2020

Although little evidence exists with regard to how to best treat patients with breast cancer during the COVID-19 pandemic, guidelines have been issued by organizations like ESMO to assist providers with making those decisions.

Ipatasertib Survival Results Continue to Impress in TNBC

May 23rd 2020

Adding ipatasertib to paclitaxel continued to demonstrate a clinically meaningful extension in overall survival in patients with triple-negative breast cancer.

Dr. Park on the Benefit of Trastuzumab Deruxtecan in HER2+ Breast Cancer

May 23rd 2020

Yeon Hee Park, MD, discusses the utility and benefit of fam-trastuzumab deruxtecan-nxki in HER2-positive metastatic breast cancer, specifically in patients with central nervous system metastases.